Spencer Hart, MD
Urology · Woodbury, MNNPI 1609294693
Payments from drug & device makers
What this record shows
This record is dominated by other: $67,167 of the $68,766 with a category attached, or 97.7%. Angiodynamics, Inc. accounts for 97.7% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $30,407, more than ten times the $310 reported in 2019. Among urology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 51 payments — averaging $1348.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$67K
- Boston Scientific$754
- Olympus America Inc.$223
- Intuitive Surgical$75
- AbbVie$61
- Coloplast$49
- plus $392 from 18 others
Across 3 payments — averaging $4510.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Olympus Corporation Of The Americas$9K
- Gyrus ACMI, Inc.$5K
What the payments were for
- Food & beverage$1,6002%
- Other$67,16798%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 4 | $67,212 |
| Boston Scientific | 15 | $754 |
| Olympus America Inc. | 5 | $223 |
| Intuitive Surgical | 1 | $75 |
| AbbVie | 4 | $61 |
| Coloplast | 2 | $49 |
| SRS Medical Systems, Inc. | 1 | $40 |
| Bayer | 2 | $36 |
| Pfizer | 2 | $33 |
| BD | 1 | $29 |
| Accord Healthcare, Inc. | 1 | $27 |
| Urogen Pharma, Inc. | 1 | $24 |
| Tempus AI, Inc | 1 | $23 |
| Blue Earth Diagnostics | 1 | $23 |
| Convatec Inc. | 1 | $18 |
| Myovant Sciences Inc. | 1 | $17 |
| ABC Home Medical Supply, Inc. | 1 | $16 |
| Progenics Pharmaceuticals, Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Teleflex LLC | 1 | $16 |
| Photocure Inc | 1 | $14 |
| Antares Pharma, Inc. | 1 | $14 |
| AstraZeneca | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nanoknife$67,167
- rezum Generator$149
- iTIND System$141
- AMS$125
- LithoVue$116
- REZUM$116
How this compares
$68,766 in reported general payments places this provider in the 95th percentile of 247 urology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 98 | $1,352,602 |
| NubeqaDarolutamide | 37 | $503,830 |
| ErleadaApalutamide | 33 | $474,614 |
| OrgovyxRelugolix | 89 | $233,601 |
| Abiraterone Acetate | 84 | $142,126 |
| MyrbetriqMirabegron | 58 | $39,304 |
| Tamsulosin Hcl | 389 | $6,063 |
| Finasteride | 223 | $3,551 |
| Oxybutynin Chloride ErOxybutynin Chloride | 135 | $2,696 |
| Potassium Citrate ErPotassium Citrate | 23 | $2,022 |
| Estradiol | 16 | $1,039 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 52 | $754 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 15 | $431 |
| Ketorolac Tromethamine | 19 | $330 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 94 | $315 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $14 | $1,391,906156 claims |
| BayerNubeqa | $36 | $503,83037 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $16 | $233,60189 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 247 urology providers in Minnesota.
Other urology in Woodbury
- Steven SiegelWoodbury$140K
- Aaron MilbankWoodbury$97K
- Jodi MichaelsWoodbury$66K
- Mikhail RegelmanWoodbury$10K
- Anthony PolcariWoodbury$7K
- Samuel KieleyWoodbury$6K
- David YangMankato$298K
- Steven BernsteinEdina$271K
- Ayman SoubraMinneapolis$204K
- Sean ElliottMinneapolis$163K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.